Successful and safe treatment of hemangioma with oral propranolol in a single institution.
10.3345/kjp.2012.55.5.164
- Author:
Sun Hee CHUNG
1
;
Dong Hyuk PARK
;
Hye Lim JUNG
;
Jae Won SHIM
;
Deok Soo KIM
;
Jung Yeon SHIM
;
Moon Soo PARK
;
Hong Hoe KOO
Author Information
1. Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. hl.jung@samsung.com
- Publication Type:Original Article
- Keywords:
Hemangioma;
Propranolol;
Treatment
- MeSH:
Cosmetics;
Hemangioma;
Humans;
Propranolol;
Recurrence;
Retrospective Studies
- From:Korean Journal of Pediatrics
2012;55(5):164-170
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Dramatic improvement of hemangioma to propranolol has been recently reported; however, details on dose and duration of treatment, potential risks, and monitoring have not been determined. The objective of this study is to describe and analyze the use of propranolol as a first-line treatment or as a single therapy in management of complicated hemangioma. METHODS: A retrospective chart review of eight patients diagnosed with hemangioma and treated with propranolol in Kangbuk Samsung Hospital from February 2010 to April 2011 was performed. RESULTS: Eight patients with hemangioma with functional impairment, cosmetic disfigurement, or rapid growth were treated with propranolol. Five patients had solitary facial hemangioma. The mean age of symptoms at onset was 5 weeks. The median age for starting propranolol treatment was 5.5 months. Propranolol at 2 mg/kg/day was finally administered in divided doses with a gradual increase. Significant regression was observed in seven patients, and shrinkage in size, softening in consistency, and decrease in redness were evident within 4 weeks. Among them, six patients were still taking propranolol, and one patient had stopped after 12 months. Other one patient did not show significant improvement with satisfactory result after 3 months of propranolol use. Treatment with propranolol was well tolerated and had few side effects. No rebound growth was observed in any of the patients. CONCLUSION: We observed that use of propranolol was very effective in treatment of hemangioma without obvious adverse effects or relapse.
